IMvigor 210, a phase II trial of atezolizumab (MPDL3280A) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC).

Genitourinary Cancer
Session Type and Session Title: 
Welcome and General Session 4: Immunotherapy for Urothelial Carcinoma
Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, and Testicular Cancers
Abstract Number: 


Poster Board Number: 
Poster Session B Board #B2
J Clin Oncol 34, 2016 (suppl 2S; abstr 355)
Jean H. Hoffman-Censits, Petros Grivas, Michiel Simon Van Der Heijden, Robert Dreicer, Yohann Loriot, Margitta Retz, Nicholas J. Vogelzang, Jose Luis Perez-Gracia, Arash Rezazadeh, Sergio Bracarda, Evan Y. Yu, Christopher J. Hoimes, Joaquim Bellmunt, David I. Quinn, Daniel Peter Petrylak, Syed A. Hussain, Na Cui, Sanjeev Mariathasan, Oyewale O. Abidoye, Jonathan E. Rosenberg; The Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; University of Virginia School of Medicine, Charlottesville, VA; Department of Cancer Medicine, Gustave Roussy, Cancer Campus, Grand Paris, Villejuif, France; Department of Urology, Klinikum rechts der Isar, TU München, Munich, Germany; US Oncology Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Department of Oncology, Clinica Universidad de Navarra, Pamplona, Spain; Norton Cancer Inst, Louisville, KY; Medical Oncology, Ospedale San Donato USL8, Istituto Toscano Tumori, Arezzo, Italy; University of Washington, Seattle Cancer Care Alliance, Seattle, WA; Case - Seidman Cancer Ctr, Cleveland, OH; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; USC Norris Comprehensive Cancer Center, Los Angeles, CA; Yale Cancer Center, New Haven, CT; University of Liverpool, Clatterbridge Cancer Centre, Liverpool, United Kingdom; Genentech, Inc., South San Francisco, CA; Genentech, San Francisco, CA; Memorial Sloan Kettering Cancer Center, New York, NY

Abstract Disclosures


Background: The ORR and survival of mUC patients (pts) who progress after platinum-based chemotherapy (pctx) are poor. Atezolizumab (atezo) reinvigorates antitumor immunity by targeting PD-L1 and has shown promising Ph 1 activity in mUC. Methods: IMvigor 210 cohort 2 (NCT02108652) enrolled 316 mUC pts who progressed during or following pctx. Pts received atezo at 1200 mg IV q3w until loss of clinical benefit. The SP142 IHC assay centrally assessed PD-L1 expression. Pts/investigators were blinded to PD-L1 status. Co-primary endpoints were confirmed ORR by RECIST v1.1 per central review (IRF) and modified (m) RECIST per investigator, which were met if null hypothesis (ORR = 10%) was rejected (α = 5%). ORR endpoints were stratified by PD-L1 tumor-infiltrating immune cell (IC) status: IC2/3, IC1/2/3, all comers. Results: Efficacy/safety-evaluable pts (N = 311) had a median age of 66 y, CrCl < 60 mL/min (35%) and ≥ 2 prior regimens for mUC (40%). Many had poor prognostic factors (Table). At 5/5/15 data cutoff (follow up ≥ 24 w), 43/47 responding pts had ongoing responses. Both IRF (Table) and mRECIST ORR correlated with IC status. Durable responses were seen including poor prognostic subgroups (Table). mDOR was not reached in any PD-L1 or prognostic subgroup. mPFS was 2.1 mo in all PD-L1 subgroups. Median treatment duration was 12 w (range 0-46). Treatment-related AEs (most commonly fatigue) occurred in 66% of pts (all Grade); 15% had G3-4 related AE and 4% had G3-4 immune-mediated AE. 27% of AEs led to dose interruption and 3% led to withdrawal. No renal toxicity was seen. Conclusions: IMvigor 210, the first Ph 2 study targeting PD-L1/PD-1 in mUC, demonstrated significantly improved ORR vs historic controls. Responses were durable and associated with higher PD-L1 IC expression; poor prognostic factors did not preclude response. Atezo was well tolerated, and a randomized Ph 3 study vs ctx is ongoing (IMvigor 211; NCT02302807). Clinical trial information: NCT02108652

n (%)IRF ORR, % (95% CI)CR, %
PD-L1 status
    IC2/3100 (32)27 (19, 37)a8
    IC1/2/3208 (67)18 (13, 24)a5
    All311 (100)15 (11, 20)a4
Poor prognostic factors
    Visceral mets243 (78)10 (7, 15)1
    Liver mets97 (31)6 (2, 13)0
    ECOG PS 1193 (62)10 (6, 15)2
    Hb < 10 g/dL68 (22)9 (3, 18)0

aP < .01